| Literature DB >> 26482111 |
Rui Pereira1, Paula Lago1,2, Raquel Faria1,3, Tiago Torres1,4.
Abstract
Preclinical Research The efficacy of anti-TNF agents in the treatment of multiple immune-mediated inflammatory diseases (IMIDs) has increased their daily use. However, concerns remain regarding their long-term safety profile. Using a literature-based review of the infectious and malignant complications of anti-TNF biologics in IMIDs including psoriasis, Rheumatoid Arthritis, and inflammatory bowel disease, this review presents current evidence relative to the safety of anti-TNF agents in the context infections and malignancy in adults with IMIDs. Treatment with anti-TNF biologics is an effective treatment option with known risks that can be mitigated by appreciating the safety aspects and via a thorough screening and continuous monitoring of the patient.Entities:
Keywords: anti-TNFa therapies; immune-mediated inflammatory diseases; infection; inflammatory bowel disease; malignancy; psoriasis; rheumatoid arthritis; safety
Mesh：
Substances：
Year: 2015 PMID： 26482111 DOI： 10.1002/ddr.21285
Source DB: PubMed Journal: Drug Dev Res ISSN： 0272-4391 Impact factor: 4.360